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Abstract: Despite the availability of over 20 antiepileptic drugs, about 30% of epileptic 
patients do not achieve seizure control. Thus, identification of additional molecules targeting 
novel molecular mechanisms is a primary effort in today’s antiepileptic drug research. This 
paper reviews the pharmacological development of retigabine, an antiepileptic drug with a novel 
mechanism of action, namely the activation of voltage-gated potassium channels of the Kv7 sub-
family. These channels, which act as widespread regulators of intrinsic neuronal excitability and 
of neurotransmitter-induced network excitability changes, are currently viewed among the most 
promising targets for anticonvulsant pharmacotherapy. In particular, the present work reviews 
the pathophysiological role of Kv7 channels in neuronal function, the molecular mechanisms 
involved in the Kv7 channel-opening action of retigabine, the activity of retigabine in preclini-
cal in vitro and in vivo studies predictive of anticonvulsant activities, and the clinical status of 
development for this drug as an add-on treatment for pharmacoresistant epilepsy. Particular 
efforts are devoted to highlighting the potential advantages and disadvantages of retigabine when 
compared with currently available compounds, in order to provide a comprehensive assessment 
of its role in therapy for treatment-resistant epilepsies.
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Introduction
Epilepsy is a disorder characterized by seizures due to recurrent, spontaneous epi-
sodes of aberrant synchronization in neuronal networks.1 It is the most common 
human neurologic disorder, with about 50 million people affected worldwide, an 
estimated prevalence of about 0.4%–1.0%, and an estimated incidence of 20–70 new 
cases/10.000 individuals.2,3
Aberrant neuronal synchronization in epilepsy can remain focal, spread to other 
sites, or engage all cortical regions simultaneously. According to the most recent 
International League Against Epilepsy (ILAE) classification, epileptic seizures can 
be classified as generalized or partial.4 Generalized epileptic seizures engage bilater-
ally distributed networks which can include cortical and subcortical structures, but do 
not necessarily include the entire cortex and can be asymmetric. On the other hand, 
focal epileptic seizures originate within networks limited to one hemisphere, may 
be discretely localized or more widely distributed, and may originate in subcortical 
structures. The latest classification of the ILAE provides new concepts for the current 
understanding of epilepsies focusing on basic neurobiologic mechanisms rather than 
the clinical manifestations of the disease.
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Except for a minority of cases which can be approached 
surgically, epilepsy treatment relies on the use of antiepilep-
tic drugs to achieve symptomatic seizure control. Over 20 
antiepileptic drugs, each with exquisite pharmacokinetics, 
spectrum of antiepileptic activity, and toxicity are currently 
available for this purpose. The mechanisms of action of 
most currently available antiepileptic drugs is restricted to 
voltage-gated sodium channels (phenytoin, carbamazepine), 
components of the γ-aminobutyric acid (GABA) system, 
including: GABA
A
 receptors (phenobarbital, benzodiaz-
epines), the GAT-1 GABA transporter (tiagabine), and 
GABA transaminase (vigabatrin); voltage-gated calcium 
channels (valproate, ethosuximide); and synaptic proteins 
involved in neurotransmitter release, such as SV2A (leveti-
racetam, brivaracetam).
Despite such a wide therapeutic armamentarium, it is 
currently estimated that about 30% of epileptic patients 
do not receive satisfactory treatment; this figure is even 
higher if one considers partial epilepsies in which develop-
mental alterations leading to identifiable changes in brain 
structure are primary underlying causes. Thus, to improve 
some of the well known limitations of current anticonvul-
sant treatment, one of the most ambitious goals in today’s 
antiepileptic research is the identification of additional mol-
ecules targeting novel molecular mechanisms involved in 
neuronal excitability control. The present paper reviews the 
preclinical and clinical development of retigabine, a novel 
antiepileptic drug targeting voltage-gated potassium (K+) 
channels of the Kv7 subfamily. These channels, by acting as 
widespread regulators of intrinsic neuronal excitability and 
of neurotransmitter-induced network excitability changes, 
are currently viewed among the most promising “druggable” 
targets for anticonvulsant pharmacotherapy.
Neuronal potassium channels  
of the Kv7 subfamily
Potassium channels with distinct subcellular localization, 
biophysical properties, modulation, and pharmacologic 
profile are primary regulators of intrinsic electrical proper-
ties of neurons and their responsiveness to synaptic inputs.5 
An increase in membrane conductance to K+ ions causes 
neuronal hyperpolarization and, in most cases, reduces firing 
frequency, exerting a strong inhibitory function on neuronal 
excitability.
Among voltage-gated K+ currents, the M-current (I
KM
) is 
a primary transducer of changes in the extracellular chemi-
cal composition into modification of the intrinsic neuronal 
properties. I
KM
 was first identified in amphibian peripheral 
neurons6 but later found to be widely distributed also in the 
mammalian peripheral and central nervous system.7 I
KM
 is 
a low-threshold, slowly activating and deactivating, and 
noninactivating voltage-dependent K+ current which limits 
repetitive firing and causes spike frequency adaptation.8 
Activation of several receptors linked to pertussis toxin-in-
sensitive G proteins of the G
q/11
 family, including M
1
, M
3
, and 
M
5
 subtypes of muscarinic receptors (hence its definition),9 
can control neuronal excitability by suppressing I
KM
.10,11
The identification of the molecular basis of I
KM
 was 
achieved in the late 1990s upon the discovery that benign 
familial neonatal seizures, a rare autosomal dominant idio-
pathic epilepsy of the newborn characterized by the occur-
rence of focal or generalized seizures starting around day 3 
of postnatal life and spontaneously disappearing after few 
weeks or months, was associated with mutations in Kv7.212,13 
or, more rarely, Kv7.3,14 both genes encoding for K+ chan-
nel subunits.
Kv7.2 and Kv7.3 belong to the Kv7 (KCNQ) subfamily 
of K+ channel genes. This subfamily is composed of five 
members, also including Kv7.1 which is expressed in several 
non-neuronal tissues including the heart, where it underlies 
the I
Ks
 current involved in the late repolarization phase of 
the cardiac action potential,15 and in epithelial cells of sev-
eral organs; Kv7.4, which is expressed in primary sensory 
cells in the inner ear and in neurons of the central auditory 
pathway,16,17 as well as in skeletal muscle,18 and visceral and 
vascular smooth muscle;19 and Kv7.5, whose transcripts have 
been detected in the brain, as well as in skeletal and smooth 
muscle cells.20 Because of their expression in the nervous 
system, Kv7.2–Kv7.5 subunits are commonly referred to as 
“neural” Kv7 subunits.21
Most of the biophysical and pharmacologic properties of 
I
KM
 in neurons are recapitulated upon heteromeric expres-
sion of Kv7.2 and Kv7.3 subunits.22,23 Functional studies in 
heterologous expression systems revealed that mutations in 
Kv7.2 and Kv7.3 genes causing benign familial neonatal 
seizures decrease the ability of I
KM
 to suppress neuronal 
excitability.24
Genetically-modified animal models further confirmed the 
specific involvement of Kv7.2 and Kv7.3 in brain excitability 
control. Heterozygous mice carrying a targeted deletion of 
the Kv7.2 gene displayed an increased sensitivity to procon-
vulsant stimuli.25 In addition, transgenic mice conditionally 
expressing mutant Kv7.2 subunits causing dominant-negative 
suppression of I
KM
 function showed signs of increased neu-
ronal excitability in hippocampal CA1 pyramidal neurons, 
spontaneous seizures, behavioral hyperactivity, and deficits 
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in hippocampus-dependent spatial memory.26 A third model 
of Kv7.2 deficiency is represented by stz1 mice carrying an 
ethylnitrosurea-induced deletion of a large genomic region 
encompassing Kv7.2; heterozygous stz1 mice, similar to 
Kv7.2 knockout mice, have a reduced electroconvulsive 
threshold and an increased sensitivity to the convulsant 
pentylenetetrazole, together with structural abnormalities in 
the hippocampal formation.27 More recently, mouse models 
carrying missense mutations that underlie human benign 
familial neonatal seizures into the orthologous murine Kv7.2 
and Kv7.3 genes have been established. While heterozygous 
mice exhibited reduced thresholds to electrically induced sei-
zures compared with wild-type littermate mice, homozygous 
mutant mice showed early-onset spontaneous generalized 
tonic-clonic seizures that triggered neuronal plasticity without 
hippocampal mossy fiber sprouting.28
Kv7 channel openers: retigabine  
and novel mechanism of action  
of anticonvulsants
Potential role of i
KM
 openers
Given the previously mentioned functional and genetic evi-
dence, activation of neuronal I
KM
 is currently considered as a 
primary strategy for pharmacologic intervention in epilepsy 
and other human diseases, such as migraine and chronic pain, 
all conditions in which neuronal hyperexcitability appears to 
play a fundamental pathogenetic role. In all these diseases, 
hyperpolarization of the resting membrane potential and 
decreased action potential generation, prompted by the acti-
vation of neuronal K+ currents in excitatory neurons, may 
result in an effective therapeutic strategy. As a matter of 
fact, compounds with I
KM
 opening abilities have undergone 
extensive preclinical and clinical investigation as potential 
antiepileptics and analgesics, even before their molecular 
mechanism of action was discovered.
History of retigabine
Retigabine (D-23129, chemical name N-(2-amino-4-
(4-fluorobenzylamino)-phenyl)-carbamic acid ethyl ester) is 
the prototype I
KM
 opener. Retigabine is a structural analog of 
flupirtine (D-9998), a triaminopyridine successfully used in 
clinical practice in some European countries since 1984 as 
a centrally acting nonopioid analgesic, also provided with 
muscle relaxant and neuroprotective actions,29,30 but devoid 
of appreciable anti-inflammatory and antipyretic activity.31
In the Antiepileptic Drug Development program supported 
by the US National Institutes of Health using in vivo animal 
screening strategies, flupirtine was shown in the late 1980s 
to have anticonvulsant activity, although at doses higher than 
those producing analgesia. Structure-activity optimization of 
flupirtine yielded retigabine, which showed more effective 
anticonvulsant activity when compared with flupirtine, being 
active in nearly every animal seizure model, with an overall 
profile different from any other known drug.32 The broad 
profile of efficacy in animal models already suggested that 
the mechanism(s) involved in the anticonvulsant actions of 
retigabine were distinct from those previously known. In the 
late 1990s, retigabine was shown to activate voltage-dependent 
neuronal K+ currents at concentrations at least 10–30 times 
lower than those producing a potentiation of GABA
A
-mediated 
currents and a weak blocking action on ligand- (kainate and 
NMDA receptors) and voltage-gated (sodium and calcium) 
channels.33,34 However, these studies failed to identify the 
precise nature of the K+ current targeted by retigabine; this was 
only possible when drug effects were evaluated on native I
KM
 
in neuronal cells and on cloned Kv7.2 and Kv7.3 channels in 
heterologous expression systems; these experiments, clearly 
demonstrated that I
KM
 formed by Kv7.2/3 subunits was the 
major molecular target for retigabine.35–37 In addition to I
KM
 
opening, both retigabine and flupirtine have been shown to 
possess antioxidant properties in vitro,29,38 a pharmacological 
property which might explain at least some of the neuroprotec-
tive effects shown by both compounds.
Mechanism of action of retigabine
The biophysical mechanism responsible for retigabine-induced 
I
KM
 potentiation is rather complex, and involves a combina-
tion of two factors, ie, a hyperpolarizing shift in the voltage-
dependence of the channel activation process and an increase 
in the maximal opening probability of these channels. Both 
these effects can contribute by a variable amount in channels 
formed by different combinations of Kv7 subunits. In fact, the 
hyperpolarizing shift is maximal for Kv7.3 (-43 mV), interme-
diate for Kv7.2 (-24 mV), smaller for Kv7.4 (-14 mV), and 
absent for Kv7.5 homomeric channels.39,40 In Kv7.5 channels, 
instead, retigabine markedly increases the current irrespective 
of the membrane potential; by contrast, in Kv7.2 and Kv7.2/3 
combinations, the maximal amount of current elicited by strong 
depolarization is not affected, whereas homomeric Kv7.4 
channels show both the shift in voltage-dependent opening 
probability and an increase in maximal conductance.39 These 
changes are accompanied by a variable degree of drug-induced 
delay in channel closure (deactivation), suggesting that the 
primary molecular consequence of the interaction of retigabine 
with the channel protein is a stabilization of the channel pore 
in the open conformation.
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Retigabine-induced enhancement of I
KM
 hyperpolarizes 
the neuronal resting membrane potential, leading to an 
inhibition of spontaneous or synaptically-triggered neuronal 
activity. Intriguingly, some mutations causing benign famil-
ial neonatal seizures in Kv7.2 prompt functional changes 
in I
KM
 biophysical properties which are opposite to those 
caused by retigabine.41 As previously mentioned, retiga-
bine affects I
KM
 underlined by all different Kv7 subunits. 
However, the potency of retigabine in causing activation 
of the channels formed by distinct Kv7 subunits appears 
slightly different, with, in most cases, Kv7.2 and Kv7.3 
showing higher (EC
50
 , 1 µM) and Kv7.4 and Kv7.5 
lower (EC
50
 . 1 µM) sensitivity to the drug.  Nevertheless, 
because these differences are quantitatively rather small, 
retigabine is currently regarded as a “nonselective” neural 
Kv7 channel opener. Noticeably, none of these actions 
are prompted by retigabine in cardiac Kv7.1 channels, an 
important observation to interpret the lack of cardiac toxic-
ity shown by this compound.
Other iKM activators
The described results firmly establish I
KM
 as a crucial target 
for pharmacological intervention in hyperexcitability dis-
eases, and have led to an explosion of interest in the identi-
fication of congeners additional to flupirtine and retigabine 
acting as I
KM
 activators. Among these, phenamates, such as 
meclofenamic acid and diclofenac, well known blockers of 
the cyclooxygenase enzymes, have been described to act as 
Kv7.2/3 K+ channel openers and to show robust antiepileptic 
properties in vivo.42 Although these pharmacological actions 
require rather high drug concentrations, these compounds 
have been suggested to represent novel drug templates for 
the treatment of neuronal hyperexcitability diseases, includ-
ing epilepsy, migraine, or neuropathic pain. Indeed, more 
recent studies demonstrated that diclofenac derivatives with 
poor (NH6)43 or absent (NH29)44 cyclooxygenase-blocking 
activity reduced neuronal excitability and/or showed anti-
convulsant effects in murine models of seizures.
The interest in I
KM
 (and in particular in Kv7.2/3 sub-
units) as a possible target in the treatment of epilepsy 
and other hyperexcitability diseases has also led to the 
development of ICA-27243, a compound belonging to the 
chemical class of substituted benzamides. In contrast with 
retigabine, which does not discriminate between channels 
formed by different Kv7 subunits, ICA-27243 showed 
high selectivity for current elicited by Kv7.2/Kv7.3 het-
erotetramers, with an EC
50
 of 0.4 µM, while its potency 
on Kv7.4 or Kv7.3/Kv7.5 channels was 20-fold and 
.100-fold lower, respectively.45 Moreover, ICA-27243 
exhibited  anticonvulsant properties in preclinical models 
of seizures.46 The search for new molecules with agonistic 
activity on Kv7 channels prompted Xiong et al to demon-
strate that zinc pyrithione is an activator of heterologous 
expressed and native I
KM
.47 Zinc pyrithione potentiated 
K+ currents elicited both by cardiac Kv7.1 and neural 
Kv7.2-5 subunits, except those sustained by Kv7.3 chan-
nels; in addition, its agonistic action was noncompetitive 
with that exerted by retigabine, giving rise to combinato-
rial effects when applied together.48 Other molecules able 
to enhance Kv7-mediated current include BMS-204352, 
originally developed as an opener of Ca2+- and voltage-
gated K+ channels, and the acrylamide compound, (S)-1. 
Although both these molecules can open channels formed 
by all neural Kv7 subunits, they display a noticeably stron-
ger action on channels formed by Kv7.4 subunits (BMS-
204352)49,50 or on Kv7.4 and Kv7.5 subunits [(S)-1].51
The binding site for retigabine  
on neuronal Kv7 channels
Results from mutagenesis and modeling experiments have 
suggested that, in channels formed by neural Kv7 subunits, 
retigabine binds to a hydrophobic pocket located between 
the cytoplasmic parts of the S
5
 and the S
6
 transmembrane 
domains in the open channel configuration. Within this 
cavity, a tryptophan residue in the intracellular end of the 
S
5
 helix (W236 in the Kv7.2 sequence) seems to play a 
crucial role.52,53 Replacement of this residue with a smaller 
and less hydrophobic amino acid (leucine) largely prevents 
the ability of retigabine to activate I
KM
. Additional amino 
acids (in Kv7.2 sequence: Leu243 in S
5
, Leu275 within 
the inner pore loop, Gly301 in the S
6
 segment, and Leu299 
in S
6
 of the neighboring subunit) seem also to be involved 
in the formation of the complete retigabine binding site54 
(see Figure 1). Except for Leu275, these amino acids are 
conserved among all neural Kv7 subunits but are missing 
in the Kv7.1 subunit primary sequence, an observation that 
may explain the lack of sensitivity to retigabine shown by 
channels formed by Kv7.1 subunits. The tryptophan in the 
S
5
 segment seems also to be important for the binding of 
other I
KM
 activators, such as S-(1) and BMS-204352, both 
molecules failing to show additive effects with retigabine.51 
Another Kv7 activator, zinc pyrithione, also seems to bind 
to the pore region, although the molecular determinants 
for such an interaction appear to be only partially overlap-
ping with those of retigabine, a result consistent with the 
additive effects on I
KM
 exerted by these two compounds.48 
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Figure 1 Panel A shows the schematic topology of a single Kv7.2 subunit, with each 
of the six transmembrane regions indicated. The green cylinders correspond to the 
S5 and S6 transmembrane regions. The amino acids involved in retigabine binding 
are indicated. Panel B shows a top view of the overall structure of the channel 
formed by four identical Kv7.2 subunits, with one retigabine molecule bound. Panel 
C shows an enlarged view of the retigabine binding site with the retigabine molecule 
docked into the channel cavity as obtained with ArgusLab 4.0.1 (Planaria Software 
LLC, Seattle, wA; available at http://www.arguslab.com). The residues involved in 
retigabine binding are indicated. The dashed yellow lines indicate the polar contacts 
between retigabine and the residues A235 and w236. Three-dimensional models 
of Kv7.2 subunits were generated by homology modelling using known structures 
of potassium channel subunits available in the Protein Data Bank), using SwiSS-
MODeL, a program that performs automated sequence-structure comparisons, as 
previously described.92 The model generated was analyzed using both the Deepview 
module of Swiss-PDBviewer (version 3.7, available at http://www.expasy.ch/spdbv/) 
and PyMOL (available at http://pymol.sourceforge.net/). in the present study, the 
homology model was built using the template structure (2R9RH) for a chimeric 
channel in which the voltage-sensor paddle (corresponding to the S3b–S4 region) of 
Kv2.1 was transferred into the Kv1.2 subunit.
93
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By contrast, phenamates (meclofenamic acid and diclofenac, 
as well as their derivatives) were still able to potentiate the 
K+ currents elicited by the Kv7.2 W236L mutant, suggest-
ing their preferential binding in a different domain of the 
channel. In fact, NH29 appears to bind in close proximity 
to the external surface of the voltage-sensing domain, at 
the interface of helices S
1
, S
2
, and S
4
, with a mechanism of 
action similar to that of gating-modifier toxins.55 Similar to 
NH29, the selective Kv7.2/Kv7.3 opener ICA-27243 was 
also found to bind to the voltage-sensing domain; the pri-
mary sequence of the region involved in ICA-27243 binding 
appears extremely variable among Kv7 subfamily members, 
allowing the drug to selectively affect channels formed by 
specific Kv7 subunits.56
In conclusion, the identification of the different regions on 
the channel molecule involved in binding distinct molecular 
entities might represent the starting point to design molecules 
selectively targeting strategic functional domains of Kv7 sub-
units, and may possibly allow for drug specificity at each 
Kv7 channel subtype. Whether this will translate into better 
efficacy and side effect profiles, and, therefore, into significant 
advantages for the treatment of hyperexcitability disorders 
with Kv7 channel openers, is still a matter of investigation.
Retigabine in preclinical models 
predictive of anticonvulsant activity
The therapeutic potential of retigabine as an antiepileptic drug 
has been assessed in several preclinical studies using various 
models. Retigabine was shown to be effective in reducing 
convulsions induced both by maximal electroshock (similarly 
to carbamazepine, phenytoin, and diazepam) and by pentyle-
netetrazole, picrotoxin, and NMDA (similarly to ethosuximide 
and valproate), two models predictive for drug efficacy in 
humans against generalized tonic–clonic, and generalized 
absence and myoclonic epilepsies, respectively.57 Moreover, 
retigabine has been also tested in genetic models of epilepsy, 
such as DBA/2 mice57 or epilepsy-prone rats (GEPR-3 and 
GEPR-9),58 ie, models possessing some predictability for 
generalized tonic–clonic seizures (DBA/2 mouse and GEPR-9 
rat) and absence seizures (GEPR-3 rat). In these three rodent 
models, retigabine was able to reduce seizures induced by loud 
noise stimulation. In addition, in DBA/2 mice, it showed an 
additive effect when administered in combination with clas-
sical anticonvulsants, most notably diazepam, phenobarbital, 
phenytoin, and valproate.59 The administration of low doses 
of retigabine (0.01 mg/kg intraperitoneally or orally) also 
increased the threshold for induction of afterdischarges in the 
amygdala-kindling model of complex partial seizures; at higher 
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doses (5 mg/kg intraperitoneally or 15 mg/kg orally) it reduced 
seizure severity and duration, total  duration of behavioral 
changes, and afterdischarge duration. The potency of retiga-
bine was much higher when compared with that of valproate; 
moreover, the doses required to increase the seizure threshold 
in amygdala-kindled rats are substantially lower than those 
needed to increase the threshold in the maximal electroshock 
test (an effect opposite to that of carbamazepine, phenytoin, 
and valproate), suggesting that retigabine is particularly effec-
tive against partial seizures.60 Seizure models used in these 
studies lack specific predictivity against pharmacoresistant 
epilepsy. The fact that retigabine recognizes a molecular target 
distinct from currently available antiepileptic drugs makes this 
molecule particularly attractive for potential efficacy in drug-
resistant epilepsies. To address this possibility, retigabine has 
been tested in vivo in lamotrigine-resistant kindled rats61 and in 
the 6 Hz psychomotor mouse model,62 two preclinical models 
of epilepsy resistant to common antiepileptic drugs including 
lamotrigine, phenytoin, carbamazepine, topiramate, tiagabine, 
and felbamate. In these models, retigabine dose-dependently 
inhibited seizures and reduced afterdischarge duration induced 
by kindling stimulation and by 32 mA or 44 mA corneal 
stimulation, respectively.63 In addition, retigabine was shown 
to reduce spontaneous bursting in hippocampal-entorhinal 
cortex slices from kainate-treated rats resistant to therapeutic 
concentrations of phenytoin, carbamazepine, and valproate,64 
and to suppress spontaneous spike waves and low magnesium 
induced-epileptiform field potential in neocortical slices pre-
pared from human patients with pharmacoresistant epilepsy 
undergoing surgical treatment.65 In conclusion, retigabine 
showed activity in a broad array of in vitro and in vivo epilepsy 
models, including some in which classical antiepileptic drugs 
failed to be effective.
Pharmacokinetics of retigabine  
in humans
Studies carried out to investigate retigabine pharmacoki-
netics in both healthy volunteers and patients mostly gave 
concordant results. The bioavailability of orally administered 
retigabine is 60%, with a very low first-pass metabolism. 
 Absorption is rapid, and plasma peak concentration is 
achieved within 1.5 hours. Food does not significantly inter-
fere with  absorption of retigabine, causing only slight delays 
in the time required to reach plasma peak concentration (up 
to two hours). Retigabine plasma protein binding is about 
80%, and the drug is widely distributed, with a volume of 
distribution of approximately 6.2 L/kg. Retigabine is metabo-
lized only by Phase II  reactions, primarily by acetylation (to 
a monoacetylated metabolite known as AWD21-360, which 
has similar  half-life but lower anticonvulsant potency when 
compared with retigabine) and glucuronidation (via UGT1A1, 
A3, A4, and A9). Glucuronidation (which also occurs for 
 AWD21-360) leads to the formation mainly of N
2
- and of a 
minor amount of N
4
-glucuronide, both possessing no anti-
epileptic activity. Of note, Phase I clinical studies pointed to 
a constant ratio between retigabine and the N
2
-glucuronide 
metabolite, suggesting that the two compounds are coupled via 
enterohepatic circulation and glucuronidation/deglucuronida-
tion reactions occurring in the liver and gut, respectively.66 
Retigabine does not induce or inhibit its own metabolism, 
and is eliminated primarily by the kidneys, with a mean ter-
minal half-life of 8.0 hours and an apparent oral clearance of 
0.70 L/h/kg. The pharmacokinetics of retigabine are linearly 
proportional to the dose. Steady-state pharmacokinetics 
were in agreement with single-dose pharmacokinetics, and 
the accumulation ratio was about 1.5.67 Only a few differ-
ences regarding race, gender, and age have been observed 
in pharmacokinetic parameters. Ferron et al reported lower 
clearance and volume of distribution for retigabine in black 
subjects (25% and 30% lower, respectively), possibly due to 
differences in N-glucuronidation. In another study, retigabine 
was found to reach higher maximum concentration (56%) 
and exposure (20%) in young women when compared with 
young men, but showed similar clearance; this variability 
likely reflected differences in body weight. In elderly sub-
jects, retigabine elimination was slower (30% lower apparent 
clearance normalized for weight), resulting in higher expo-
sure (42%) and longer half-life (30%), although maximum 
concentration was similar to that in adults. These differences 
have been attributed to the decline of renal function with 
age.68 No significant alterations in tolerability and safety were 
found in subjects with polymorphisms in the UGT1A1 (ie, 
Gilbert’s syndrome) and/or in N-acetyltransferase, NAT2 (ie, 
fast or slow acetylator) after a single and multiple (twice daily) 
200 mg dose of oral retigabine administered over five days, 
although the total exposure to the monoacetylated metabo-
lite, AWD21-360, was significantly related to the fast or 
slow acetylator status of subjects.69 In vitro assays in human 
liver microsomal preparations showed that 6 µM retigabine 
(a concentration similar to the peak concentration in subjects 
receiving a therapeutic dose of the drug) has a moderate capac-
ity to inhibit cytochrome (CYP)2A6 and low or no potential 
to inhibit CYP1A2, CYP2C8/9/19, CYP2D6, CYP2E1, 
CYP3A4/5, and CYP4A9/11. According to these studies, no 
clinically relevant inhibition of CYP-mediated drug metabo-
lism is expected. The potential for drug-drug interaction due 
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to competition for glucuronidation was investigated using 
valproic acid, lamotrigine, imipramine, and propofol, com-
monly used medications which are extensively glucuroni-
dated. When assayed with human liver microsomes or UGT1 
A9 enzyme, no interactions were found at clinically relevant 
concentrations.70 Moreover, no clinically significant interac-
tions between retigabine and phenobarbital were reported in 
clinical studies in healthy subjects.71 By contrast, patients 
already treated with phenytoin and carbamazepine (two drugs 
known to induce UGT enzymes) showed an increased clear-
ance of retigabine by 36% and 27%, respectively. Valproate 
and topiramate coadministration did not modify retigabine 
pharmacokinetics. Retigabine did not alter the pharmacoki-
netic profile of phenytoin, carbamazepine, valproate, pheno-
barbital, and topiramate.72 Although in this latter study no 
significant interactions were observed in patients receiving 
retigabine in addition to lamotrigine, Hermann et al reported a 
modest reciprocal pharmacokinetic interaction between these 
two antiepileptic drugs; lamotrigine reduced the clearance of 
retigabine by 13%, while it increased the mean half-life and 
the area under the plasma concentration-time curve (AUC) 
by 7.5% and 15%, respectively. Retigabine also influenced 
lamotrigine pharmacokinetics, by increasing its clearance (by 
22%) and reducing its mean half-life (by 15%) and AUC (by 
18%).73 While the reduced clearance of retigabine induced 
by lamotrigine is explained by the authors as competition 
for renal excretion, the effect of retigabine on lamotrigine 
pharmacokinetics remains unclear, because retigabine did not 
show enzyme induction in various other drug-drug interaction 
studies. Retigabine did not decrease contraceptive hormone 
exposure in women taking a low-dose oral contraceptive 
(ethinyl estradiol 0.035 mg + norethindrone 1 mg), suggesting 
no potential for reducing contraceptive efficacy. Moreover, 
the AUC values of retigabine measured in women receiving 
such combination therapy were not significantly different 
from those reported in other studies, suggesting that oral 
contraceptives did not alter retigabine pharmacokinetics.72
Efficacy studies with retigabine
Retigabine efficacy in the treatment of partial onset seizures 
has been assessed by multicenter, randomized, double-blind, 
placebo-controlled Phase II and Phase III clinical trials 
(Table 1).
Phase ii studies
A Phase II study74,75 was conducted to evaluate the 16-week 
(eight-week titration phase, eight-week maintenance phase) 
efficacy and safety of retigabine 600, 900, and 1200 mg/day 
(divided into three daily doses) versus placebo as an  adjunctive 
therapy in partial onset seizures. Patients enrolled in this trial 
(n = 396) were men and women 16–70 years of age, with 
incomplete control of seizures despite therapy with 1–2 
antiepileptic drugs or vagal nerve stimulation treatment 
(considered as an antiepileptic drug if stimulation parameters 
were kept constant during the study), which did not have to 
be discontinued throughout the study. Patients had to experi-
ence at least four partial onset seizures per month (with or 
without secondary generalization) in the eight-week base-
line period, and no 30-day seizure-free period. The results 
of this study showed that retigabine caused a significant 
and dose-dependent reduction in median percent monthly 
seizure frequency from baseline by 23% (600 mg/day), by 
29% (900 mg/day), and by 35% (1200 mg/day); in the pla-
cebo group the reduction was by 13%. The responders rates 
(patients with $50% seizure frequency reduction) were 23%, 
32%, and 33% in the 600, 900, and 1200 mg/day groups, 
respectively, versus 16% in the placebo arm). It is interest-
ing to note that the difference between the 600 mg/day arm 
and placebo group was not statistically significant. A total of 
222 patients who completed the double-blind 16-week trial 
entered an open-label extension study, in which the retigabine 
dose was converted to 900 mg/day. Following this, each 
patient’s daily dose of retigabine or concomitant antiepileptic 
drugs could be either reduced or increased up to a maximum 
allowed dose of 1200 mg retigabine. The median decrease 
in monthly total partial seizure frequency from baseline was 
48.3% and the responders rate was 46.4%.72,76
Phase iii studies
Based on the positive results of the Phase II study, two mul-
ticenter, double-blind, placebo-controlled Phase III registra-
tion trials investigating the efficacy of retigabine as add-on 
therapy in the treatment of refractory partial onset epilepsy, 
called RESTORE 1 and RESTORE 2, have been performed 
and recently completed. Patients enrolled in these two stud-
ies showed similar clinical features to those of the Phase II 
clinical trial (18–75 years of age, partial onset epilepsy with 
or without secondary generalization, refractory to stable 
therapy with 1–3 approved antiepileptic drugs, $ four sei-
zures per month and no 21-day seizure-free period during 
the eight-week baseline period), but differed in the target 
dosage and titration phase duration. In RESTORE 1, the 
target dose of retigabine was 1200 mg/day titrated over six 
weeks and with dosage adjustment allowed (to a minimum 
of 1050 mg/day); in RESTORE 2, retigabine 600 and 
900 mg/day were administered, titrated over 2–4 weeks and 
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Table 1 Summary of Phase ii and Phase iii clinical trials with retigabine
Phase II Phase III
Study 205 Study 301 (RESTORE 1) Study 302 (RESTORE 2)
Patients Age: 16–70 years
Gender: men and women
Clinical features: partial onset  
epilepsy ($4 seizures/month;  
no 30-day seizure-free period 
in the baseline period)
Concomitant therapy: 1–2 standard  
AeDs (vP, CMZ, PHT, TPR,  
LMT, GBP); vNS
Age: 18–75 years
Gender: men and women
Clinical features: partial onset  
epilepsy ($4 seizures/month;  
no 21-day seizure-free period in  
the baseline period)
Concomitant therapy: 1–3 standard 
AeDs (vP, CMZ, PHT, TPR,  
LMT, GBP); vNS
Age: 18–75 years
Gender: men and women
Clinical features: partial onset 
epilepsy ($4 seizures/month;  
no 21-day seizure-free period in 
the baseline period)
Concomitant therapy: 
1–3 standard AeDs (vP, CMZ, 
PHT, TPR, LMT, GBP); vNS
Patients (n) 396 256 471
Dose of RT 1200 mg/day (400 mg tid)
900 mg/day (300 mg tid)
600 mg/day (200 mg tid)
No change of dose allowed
1200 mg/day (400 mg tid)
Dose reduction allowed  
(to 1050 mg/day)
900 mg/day (300 mg tid)
600 mg/day (200 mg tid)
No change of dose allowed
Study design 8-week baseline period
8-week forced titration period
8-week maintenance period
8-week baseline period
6-week forced titration period
12-week maintenance period
8-week baseline period
4-week forced titration period
12-week maintenance period
Median seizure 
frequency reduction
23% in 600 mg/day RT arm*
29% in 900 mg/day RT arm
35% in 1200 mg/day RT arm
13% in placebo arm
44% in RT arm
17.5% in placebo arm
27.9% in 600 mg/day RT arm
39.9% in 900 mg/day RT arm
17.5% in placebo arm
Responders rate 23% in 600 mg/day RT arm
32% in 900 mg/day RT arm
33% in 1200 mg/day RT arm
16% in placebo arm
45% in RT arm
18% in placebo arm
31.5% in 600 mg/day RT arm
39.3% in 900 mg/day RT arm
17.3% in placebo arm
Adverse events Somnolence, confusion,  
dizziness, headache, asthenia
Somnolence, dizziness, headache,  
confusion, asthenia
Somnolence, dizziness, headache, 
confusion, asthenia
Open-label  
extension
Number of patients: 222
RT dose: 900 mg/day (up to  
1200 mg/day)
Median seizure frequency  
reduction: 48.3%
Responders rate: 46.4%
Ae: somnolence, confusion,  
dizziness, headache, asthenia
Number of patients: 181
RT dose: 600–1200 mg/day (mean dose 
1052 mg/day); modification of dose  
(of RT and other AeDs) allowed
Duration: 357 days (trial ongoing)
Median seizure frequency  
reduction: 57%
Responders rate: 57%
Seizure frequency  
reduction .75%: 29.6%
6-month seizure free period: 10%
Ae: dizziness, somnolence, urinary  
or renal disorders, headache
Number of patients: 375
RT dose: 600–1200 mg/day 
(mean dose 861 mg/day); 
modification of dose (of RT  
and other AeDs) allowed
Duration: 275 days (trial ongoing)
Median seizure frequency 
reduction: 53%
Responders rate: 54%
Seizure frequency  
reduction .75%: 24%
6-month seizure free period: 8%
Ae: dizziness, somnolence, 
headache, asthenia
Note: *Not statistically different versus placebo.
Abbreviations: Ae, adverse events; RT, retigabine; vP, valproate; CMZ, carbamazepine; PHT, phenytoin; TPR, topiramate; LMT, lamotrigine; GBP, gabapentin; vNS, vagal 
nerve stimulation.
with no change in the dosage allowed. The maintenance 
period was 12 weeks, with the possibility to continue with 
flexible dosing of the drug in an open-label extension of 
the studies. In both trials, retigabine significantly reduced 
the median percent in 28-day total partial seizure frequency 
from baseline (-44% in the RESTORE 1 1200 mg/day 
arm versus -17.5% in the placebo group; -39.9% in the 
RESTORE 2 900 mg/day and -27.9% in the RESTORE 2 
600 mg/day arms versus -15.9% in the placebo group). The 
responder rate from baseline to maintenance phase were also 
 significantly higher than  placebo in all the arms considered 
(45% for 1200 mg/day versus 18% for placebo; 39.3% and 
31.5% for 900 mg/day and for 600 mg/day, respectively, 
versus 17.3% for placebo).72
Safety and tolerability
The potential toxicity of retigabine was investigated in 
many preclinical studies conducted in rat and mouse models 
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of seizures.57,59,60 In general, acute toxicity was limited to 
dose-related effects on the central nervous system,  including 
hyperkinesia or hypokinesia, disturbed coordination, stilted 
gait, tremor, and convulsions.72 Moreover, retigabine did 
not exert any toxic effect on cardiac function and on electro-
cardiographic parameters, but it was able to induce urinary 
retention, an action explained by the activation of Kv7 chan-
nels expressed in smooth muscle of the bladder combined 
with inhibitory effects on afferent nerve fiber activity.77 No 
teratogenic and/or reproductive effects were observed in 
rats and rabbits.
In humans, the safety profile of retigabine has been 
investigated in large Phase II and III (RESTORE 1 and 
RESTORE 2) trials and their extension studies. In these 
studies, retigabine was used as additional therapy in patients 
already receiving 1–3 “classical” antiepileptic drugs. Thus, 
data concerning the efficacy and safety of retigabine in the 
form of monotherapy are lacking. As in animal models 
and similar to other antiepileptic drugs, retigabine showed 
minor and nonspecific adverse events involving the central 
nervous system, the most common of which were dizziness, 
somnolence, headache, and asthenia. These adverse events 
were generally dose-related, rarely serious, or a cause for 
discontinuation. Both in Phase II and III clinical trials, a 
large proportion of them occurred during the forced titra-
tion phase, and the proportion of patients withdrawing from 
the study was inversely related to the duration of the titra-
tion phase.2 The most common reasons for discontinuation 
were dizziness, confusion, somnolence, and asthenia, with 
the highest proportion of withdrawals in patients receiving 
retigabine 1200 mg/kg.72 In RESTORE 1, where retigabine 
was used at 1200 mg/kg, urinary or renal disorders were 
observed in 12% of patients. Among urinary disorders, 
urinary hesitancy was the most frequent adverse event. How-
ever, urinary adverse events did not correlate with objective 
assessments of urinary function, and most patients were 
able to continue on medication, while in all other patients 
(except one), this symptom disappeared after discontinu-
ation. Although urinary adverse effects do not seem to be 
severe, retigabine should be used with caution in patients at 
risk for urinary dysfunction (benign prostatic hyperplasia, 
neurogenic bladder), in subjects with cognitive impairment, 
and in individuals already treated with drugs active on the 
bladder (anticholinergics).78 As suggested by preclinical stud-
ies, retigabine did not exert any adverse effects on cardiac 
function, and did not prolong the QT interval. However, a 
study of cardiac conduction demonstrated that retigabine 
produced a slight (on average approximately 4 msec in the 
24 hours postdosing) and transient QT-prolonging effect in 
healthy volunteers receiving 1200 mg/day. Although this 
extent of QT prolongation may have poor clinical relevance, 
retigabine should be administered with caution in patients at 
highest risk for arrhythmia.78
Patient-focused perspectives
Due to the limited clinical experience with retigabine, data 
regarding quality of life, patient satisfaction, and adherence 
to therapy are rather scarce. However, the most frequent 
adverse events related to retigabine are similar to those 
caused by many other neuroactive drugs,74 and they should 
not worsen quality of life more than other commonly used 
antiepileptic drugs. Moreover, the clinical relevance of such 
adverse events as a cause of discontinuation of treatment 
might be less severe than that predicted by controlled tri-
als because, in these studies, contrary to common clinical 
practice, little or no adjustment of dose was allowed, thus 
increasing the rate of treatment-emergent adverse events and 
of subsequent interruption of therapy. The lack of clinically 
significant cardiac, hematologic, and hepatic toxicity (which 
can be associated, although not frequently, with treatment 
with other antiepileptic drugs, including phenytoin, carbam-
azepine, or valproate), the inability to induce or inhibit liver 
enzymes (that can reduce the efficacy of concomitant admin-
istered drug and, in particular, of contraceptive therapy), 
as well as the minimal clinical significance of drug-drug 
interactions, suggest that retigabine is a well tolerated new 
antiepileptic drug.
Conclusion
Nearly 30% of epileptic patients are resistant to pharmacolog-
ical treatment, with persistence of frequent seizures despite 
assumption of one or more antiepileptic drugs. Uncontrolled 
seizures interfere with daily life, affecting lifespan (increased 
incidence of injuries and of sudden unexplained death),79 
and global quality of life (limitations on driving or job 
availability), causing a condition of “social disability”. Phar-
macoresistant epilepsy has been associated with increased 
cognitive impairment80 and psychiatric disorders, such as 
depression.81 Despite the availability of several antiepileptic 
drugs, the probability of obtaining seizure control diminishes 
progressively with successive antiepileptic drug regimens, 
and the success of therapy is only 4%–7% on the third drug 
used or on a combination of two antiepileptic drugs in an 
add-on regimen.82 This reduced efficacy of commonly used 
medications may, in part, be a consequence of combining 
drugs with similar mechanisms of action. Moreover, antiepi-
leptic drugs are frequently involved in wide and reciprocal 
drug-drug interactions, with increased frequency of adverse 
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events and subsequent reduced tolerability for patients.83 In 
this context, retigabine, with its different mechanism of action 
and its broad spectrum of activity demonstrated in numerous 
seizure and epilepsy models and suggested by Phase II and 
III clinical trials, could play an important role in the treat-
ment of pharmacoresistant epilepsies. Moreover, retigabine 
and other neural Kv7 openers may be safe and useful tools 
for the treatment of pediatric epilepsy. Indeed, the role of 
I
KM
 in reducing neuronal excitability is particularly relevant 
in early life; due to the excitatory effect of GABAergic 
neurotransmission in the immature brain, I
KM
 represents 
the main inhibitory conductance in neonatal neurons.84 The 
importance of I
KM
 as a “brake” on neuronal excitability in 
newborns is also suggested by the natural clinical history of 
benign familial neonatal seizures, in which seizures spon-
taneously disappear after a few weeks or months, and by 
several in vitro studies showing that epileptiform activity 
caused by the pharmacological suppression of I
KM
 decreased 
or disappeared with neuronal maturation.85,86 Moreover, it 
has been demonstrated that, in hippocampal neurons, I
KM
 
density increased after birth, causing the disappearance of 
intrinsic bursting and abnormal neuronal synchronization 
characteristic of the neonatal period.87 Based on these data, 
I
KM
 can represent a fascinating therapeutic target for the 
treatment of neonatal epilepsy, also in consideration of the 
fact that first-line drugs given to neonates (usually phenobar-
bital and phenytoin) are effective in less than 50% of cases88 
and that they have been demonstrated to cause widespread 
neuronal apoptosis when given to young rodents, thus rais-
ing concerns about their administration to children.89 On 
these premises, flupirtine has been demonstrated to be more 
effective than phenobarbital and diazepam in arresting kain-
ate- and flurothyl-induced seizures when administered in rats 
at postnatal day 10.90 Moreover, in another study, retigabine 
has been shown to delay the development of focal seizures 
in postnatal day 14 rats, and to prevent the establishment of 
kindling-induced enhanced seizure susceptibility. Interest-
ingly, in the latter study, the effect of retigabine appeared to 
be more pronounced in younger animals when compared with 
older ones.91 Although these results argue in favor of the use 
of retigabine also in young children, further investigations 
are needed to demonstrate the efficacy and safety of this 
drug in the treatment of seizures occurring at early develop-
mental stages, with special regard to the possible differences 
in pharmacokinetics (such as the decreased metabolism of 
retigabine due to the reduced glucuronidation capability of 
the newborn) which can enhance the frequency and severity 
of the side effects of retigabine in these patients.
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